Daiichi Sankyo Espha, a generics subsidiary of Daiichi Sankyo Company, Limited has launched nine new generic drugs with three new active ingredients.
The products: Broad-spectrum oral antibacterial agent, levofloxacin tablets 250mg, 500mg, levofloxacin granules 10% “DSEP” (Cravit); Persistent angiotensin II receptor antagonist, candesartan tablets 2mg, 4mg, 8mg, 12mg “DSEP”(Blopress); Anti-malignant tumor agent, oxaliplatin IV infusion solution 50mg,100mg “DSEP”(Elplat IV infusion solution.
Daiichi Sankyo Espha’s levofloxacin tablets 250mg, 500mg and granules 10% “DSEP” (levofloxacin formulation) are an authorized generic drug manufactured from the same substance and additives and using the same manufacturing methods as the broad-spectrum oral antibacterial agent Cravit tablets 250mg, 500mg and granules 10% (Cravit).
Daiichi Sankyo Espha will continue to collaborate with Daiichi Sankyo to meet the needs of patients and medical practitioners by promoting the appropriate usage of antibacterial drugs. Meanwhile, regarding Cravit, Daiichi Sankyo will continue to provide information on efficacy and safety to medical practitioners based on accumulated usage results up to now.
Daiichi Sankyo Espha has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group. Thanks to initiatives such as the world’s first double-sided printing on tablets, Daiichi Sankyo Espha has contributed to increasing product added value through innovations in formulations and labeling to make drugs easier to ingest and harder for patients to mistakenly take. The company hopes to provide more appropriate generic drug options for patients and medical institutions in the future by further adding to the current authorized generic product lineup.
Daiichi Sankyo Espha was created in April 2010 to manufacture and market generic drugs and accommodate rising demand based on the spirit of Daiichi Sankyo Group corporate philosophy of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide pharmaceuticals that provide peach of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.